{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:42:28Z","timestamp":1760784148685},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2016,6,30]],"date-time":"2016-06-30T00:00:00Z","timestamp":1467244800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1245\/s10434-016-5364-3","type":"journal-article","created":{"date-parts":[[2016,6,30]],"date-time":"2016-06-30T22:21:21Z","timestamp":1467325281000},"page":"3093-3099","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["The Impact of Neoadjuvant Treatment on Surgical Options and Outcomes"],"prefix":"10.1245","volume":"23","author":[{"given":"Beyhan","family":"Ataseven","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunter","family":"von Minckwitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,6,30]]},"reference":[{"key":"5364_CR1","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/1097-0142(19830301)51:5<763::AID-CNCR2820510502>3.0.CO;2-C","volume":"51","author":"GN Hortobagyi","year":"1983","unstructured":"Hortobagyi GN, Blumenschein GR, Spanos W, et al. Multimodal treatment of locoregionally advanced breast cancer. Cancer. 1983;51:763\u20138.","journal-title":"Cancer."},{"key":"5364_CR2","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1200\/JCO.2003.01.136","volume":"21","author":"M Kaufmann","year":"2003","unstructured":"Kaufmann M, von Minckwitz G, Smith R, et al. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol. 2003;21:2600\u20138.","journal-title":"J Clin Oncol."},{"key":"5364_CR3","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1200\/JCO.1997.15.7.2483","volume":"15","author":"B Fisher","year":"1997","unstructured":"Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 1997;15:2483\u201393.","journal-title":"J Clin Oncol."},{"key":"5364_CR4","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1200\/JCO.2007.15.0235","volume":"26","author":"P Rastogi","year":"2008","unstructured":"Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008;26:778\u201385.","journal-title":"J Clin Oncol."},{"key":"5364_CR5","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.2008.19.2567","volume":"27","author":"L Gianni","year":"2009","unstructured":"Gianni L, Baselga J, Eiermann W, et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. J Clin Oncol. 2009;27:2474\u201381.","journal-title":"J Clin Oncol."},{"key":"5364_CR6","doi-asserted-by":"crossref","first-page":"4224","DOI":"10.1200\/JCO.2001.19.22.4224","volume":"19","author":"JA Hage van der","year":"2001","unstructured":"van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol. 2001;19:4224\u201337.","journal-title":"J Clin Oncol."},{"key":"5364_CR7","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.1200\/JCO.2003.12.005","volume":"21","author":"HD Bear","year":"2003","unstructured":"Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2003;21:4165\u201374.","journal-title":"J Clin Oncol."},{"key":"5364_CR8","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0140-6736(09)61964-4","volume":"375","author":"L Gianni","year":"2010","unstructured":"Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet. 2010;375:377\u201384.","journal-title":"Lancet."},{"key":"5364_CR9","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","volume":"13","author":"L Gianni","year":"2012","unstructured":"Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13:25\u201332.","journal-title":"Lancet Oncol."},{"key":"5364_CR10","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1200\/JCO.2010.31.4930","volume":"29","author":"M Untch","year":"2011","unstructured":"Untch M, Fasching PA, Konecny GE, et al. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol. 2011;29:3351\u20137.","journal-title":"J Clin Oncol."},{"key":"5364_CR11","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S1470-2045(11)70397-7","volume":"13","author":"M Untch","year":"2012","unstructured":"Untch M, Loibl S, Bischoff J, et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol. 2012;13:135\u201344.","journal-title":"Lancet Oncol."},{"key":"5364_CR12","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1200\/JCO.2009.23.8451","volume":"28","author":"M Untch","year":"2010","unstructured":"Untch M, Rezai M, Loibl S, et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol. 2010;28:2024\u201331.","journal-title":"J Clin Oncol."},{"key":"5364_CR13","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","volume":"24","author":"A Schneeweiss","year":"2013","unstructured":"Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013;24:2278\u201384.","journal-title":"Ann Oncol."},{"key":"5364_CR14","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0140-6736(11)61847-3","volume":"379","author":"J Baselga","year":"2012","unstructured":"Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2012;379:633\u201340.","journal-title":"Lancet."},{"key":"5364_CR15","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1200\/JCO.2007.14.4147","volume":"26","author":"C Liedtke","year":"2008","unstructured":"Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26:1275\u201381.","journal-title":"J Clin Oncol."},{"key":"5364_CR16","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa1111065","volume":"366","author":"G Minckwitz von","year":"2012","unstructured":"von Minckwitz G, Eidtmann H, Rezai M, et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med. 2012;366:299\u2013309.","journal-title":"N Engl J Med."},{"key":"5364_CR17","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(14)70160-3","volume":"15","author":"G Minckwitz von","year":"2014","unstructured":"von Minckwitz G, Schneeweiss A, Loibl S, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol. 2014;15:747\u201356.","journal-title":"Lancet Oncol."},{"key":"5364_CR18","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s10549-010-1228-x","volume":"125","author":"G Minckwitz von","year":"2011","unstructured":"von Minckwitz G, Untch M, Nuesch E, et al. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neoadjuvant chemotherapy trials. Breast Cancer Res Treat. 2011;125:145\u201356.","journal-title":"Breast Cancer Res Treat."},{"key":"5364_CR19","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1200\/JCO.2009.22.4725","volume":"28","author":"DP Silver","year":"2010","unstructured":"Silver DP, Richardson AL, Eklund AC, et al. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol. 2010;28:1145\u201353.","journal-title":"J Clin Oncol."},{"key":"5364_CR20","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1200\/JCO.2008.20.7019","volume":"28","author":"T Byrski","year":"2010","unstructured":"Byrski T, Gronwald J, Huzarski T, et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol. 2010;28:375\u20139.","journal-title":"J Clin Oncol."},{"key":"5364_CR21","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1093\/annonc\/mdq041","volume":"21","author":"XS Chen","year":"2010","unstructured":"Chen XS, Nie XQ, Chen CM, et al. Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer. Ann Oncol. 2010;21:961\u20137.","journal-title":"Ann Oncol."},{"key":"5364_CR22","doi-asserted-by":"crossref","first-page":"4227","DOI":"10.1002\/cncr.25309","volume":"116","author":"HR Chang","year":"2010","unstructured":"Chang HR, Glaspy J, Allison MA, et al. Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment. Cancer. 2010;116:4227\u201337.","journal-title":"Cancer."},{"key":"5364_CR23","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S1470-2045(15)00542-2","volume":"17","author":"M Untch","year":"2016","unstructured":"Untch M, Jackisch C, Schneeweiss A, et al. Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial. Lancet Oncol. 2016;17:345\u201356.","journal-title":"Lancet Oncol."},{"key":"5364_CR24","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384:164\u201372.","journal-title":"Lancet."},{"key":"5364_CR25","first-page":"CD005002","volume":"2","author":"JS Mieog","year":"2007","unstructured":"Mieog JS, van der Hage JA, van de Velde CJ. Preoperative chemotherapy for women with operable breast cancer. Cochrane Database Systematic Rev. 2007;2:CD005002.","journal-title":"Cochrane Database Systematic Rev."},{"key":"5364_CR26","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","volume":"30","author":"G Minckwitz von","year":"2012","unstructured":"von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30:1796\u2013804.","journal-title":"J Clin Oncol."},{"key":"5364_CR27","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/01.sla.0000197714.14318.6f","volume":"243","author":"AB Chagpar","year":"2006","unstructured":"Chagpar AB, Middleton LP, Sahin AA, et al. Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy. Ann Surg. 2006;243:257\u201364.","journal-title":"Ann Surg."},{"key":"5364_CR28","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s40064-016-1800-x","volume":"5","author":"T Fukuda","year":"2016","unstructured":"Fukuda T, Horii R, Gomi N, et al. Accuracy of magnetic resonance imaging for predicting pathological complete response of breast cancer after neoadjuvant chemotherapy: association with breast cancer subtype. SpringerPlus. 2016;5:152.","journal-title":"SpringerPlus."},{"key":"5364_CR29","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/SLA.0b013e3181c5dda3","volume":"251","author":"ME Straver","year":"2010","unstructured":"Straver ME, Loo CE, Rutgers EJ, et al. MRI-model to guide the surgical treatment in breast cancer patients after neoadjuvant chemotherapy. Ann Surg. 2010;251:701\u20137.","journal-title":"Ann Surg."},{"key":"5364_CR30","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1245\/s10434-015-4918-0","volume":"23","author":"B Schaefgen","year":"2016","unstructured":"Schaefgen B, Mati M, Sinn HP, et al. Can routine imaging after neoadjuvant chemotherapy in breast cancer predict pathologic complete response? Ann Surg Oncol. 2016;23:789\u201395.","journal-title":"Ann Surg Oncol."},{"key":"5364_CR31","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1038\/bjc.2013.473","volume":"109","author":"ML Marinovich","year":"2013","unstructured":"Marinovich ML, Macaskill P, Irwig L, et al. Meta-analysis of agreement between MRI and pathologic breast tumour size after neoadjuvant chemotherapy. Br J Cancer. 2013;109:1528\u201336.","journal-title":"Br J Cancer."},{"key":"5364_CR32","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1038\/bjc.2015.381","volume":"113","author":"J Heil","year":"2015","unstructured":"Heil J, Kummel S, Schaefgen B, et al. Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques. Br J Cancer. 2015;113:1565\u201370.","journal-title":"Br J Cancer."},{"key":"5364_CR33","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/SLA.0b013e3182805c4a","volume":"257","author":"EA Mittendorf","year":"2013","unstructured":"Mittendorf EA, Buchholz TA, Tucker SL, et al. Impact of chemotherapy sequencing on local-regional failure risk in breast cancer patients undergoing breast-conserving therapy. Ann Surg. 2013;257:173\u20139.","journal-title":"Ann Surg."},{"key":"5364_CR34","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1097\/SLA.0000000000001417","volume":"262","author":"M Golshan","year":"2015","unstructured":"Golshan M, Cirrincione CT, Sikov WM, et al. Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance). Ann Surg. 2015;262:434\u20139; discussion 438\u20139.","journal-title":"Ann Surg."},{"key":"5364_CR35","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1200\/JCO.1998.16.8.2672","volume":"16","author":"B Fisher","year":"1998","unstructured":"Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16:2672\u201385.","journal-title":"J Clin Oncol."},{"key":"5364_CR36","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/oxfordjournals.jncimonographs.a003469","volume":"30","author":"N Wolmark","year":"2001","unstructured":"Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2001; 30:96\u2013102.","journal-title":"J Natl Cancer Inst Monogr."},{"key":"5364_CR37","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1245\/s10434-015-4921-5","volume":"23","author":"SK Swisher","year":"2016","unstructured":"Swisher SK, Vila J, Tucker SL, et al. Locoregional control according to breast cancer subtype and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast-conserving therapy. Ann Surg Oncol. 2016;23:749\u201356.","journal-title":"Ann Surg Oncol."},{"key":"5364_CR38","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1245\/s10434-015-4603-3","volume":"23","author":"W Truin","year":"2016","unstructured":"Truin W, Vugts G, Roumen RM, et al. Differences in response and surgical management with neoadjuvant chemotherapy in invasive lobular versus ductal breast cancer. Ann Surg Oncol. 2016;23:51\u20137.","journal-title":"Ann Surg Oncol."},{"key":"5364_CR39","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1245\/s10434-006-9011-2","volume":"13","author":"S Loibl","year":"2006","unstructured":"Loibl S, von Minckwitz G, Raab G, et al. Surgical procedures after neoadjuvant chemotherapy in operable breast cancer: results of the GEPARDUO trial. Ann Surg Oncol. 2006;13:1434\u201342.","journal-title":"Ann Surg Oncol."},{"key":"5364_CR40","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10549-014-2861-6","volume":"144","author":"S Loibl","year":"2014","unstructured":"Loibl S, Volz C, Mau C, et al. Response and prognosis after neoadjuvant chemotherapy in 1051 patients with infiltrating lobular breast carcinoma. Breast Cancer Res Treat. 2014;144:153\u201362.","journal-title":"Breast Cancer Res Treat."},{"key":"5364_CR41","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s10549-013-2751-3","volume":"142","author":"F Petrelli","year":"2013","unstructured":"Petrelli F, Barni S. Response to neoadjuvant chemotherapy in ductal compared to lobular carcinoma of the breast: a meta-analysis of published trials including 1764 lobular breast cancer. Breast Cancer Res Treat. 2013;142:227\u201335.","journal-title":"Breast Cancer Res Treat."},{"issue":"4","key":"5364_CR42","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1245\/s10434-014-4122-7","volume":"22","author":"B Ataseven","year":"2014","unstructured":"Ataseven B, Lederer B, Blohmer JU, et al. Impact of multifocal or multicentric disease on surgery and locoregional, distant and overall survival of 6134 breast cancer patients treated with neoadjuvant chemotherapy. Ann Surg Oncol. 2014;22(4):1118\u201327.","journal-title":"Ann Surg Oncol."},{"key":"5364_CR43","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.1200\/JCO.2006.07.6067","volume":"24","author":"JL Oh","year":"2006","unstructured":"Oh JL, Dryden MJ, Woodward WA, et al. Locoregional control of clinically diagnosed multifocal or multicentric breast cancer after neoadjuvant chemotherapy and locoregional therapy. J Clin Oncol. 2006;24:4971\u20135.","journal-title":"J Clin Oncol."},{"key":"5364_CR44","unstructured":"NCCN. NCCN Guidelines Version 1, 2016. http:\/\/www.nccn.org ."},{"key":"5364_CR45","unstructured":"AGO. Empfehlungen gyn\u00e4kologischen Onkologie Kommission Mamma. http:\/\/www.ago-online.de , 2016."},{"key":"5364_CR46","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3233\/BD-2006-22108","volume":"22","author":"MR Kell","year":"2005","unstructured":"Kell MR, Morrow M. Surgical aspects of inflammatory breast cancer. Breast Dis. 2005;22:67\u201373.","journal-title":"Breast Dis."},{"key":"5364_CR47","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.ejso.2011.07.009","volume":"37","author":"E Monrigal","year":"2011","unstructured":"Monrigal E, Dauplat J, Gimbergues P, et al. Mastectomy with immediate breast reconstruction after neoadjuvant chemotherapy and radiation therapy: a new option for patients with operable invasive breast cancer: results of a 20\u00a0years single-institution study. Eur J Surg Oncol. 2011;37:864\u201370.","journal-title":"Eur J Surg Oncol."},{"key":"5364_CR48","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s10549-011-1437-y","volume":"127","author":"C Eriksen","year":"2011","unstructured":"Eriksen C, Frisell J, Wickman M, Lidbrink E, Krawiec K, Sandelin K. Immediate reconstruction with implants in women with invasive breast cancer does not affect oncological safety in a matched cohort study. Breast Cancer Res Treat. 2011;127:439\u201346.","journal-title":"Breast Cancer Res Treat."},{"key":"5364_CR49","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.ejso.2013.02.015","volume":"39","author":"MV Schaverien","year":"2013","unstructured":"Schaverien MV, Munnoch DA. Effect of neoadjuvant chemotherapy on outcomes of immediate free autologous breast reconstruction. Eur J Surg Oncol. 2013;39:430\u20136.","journal-title":"Eur J Surg Oncol."},{"issue":"7","key":"5364_CR50","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1245\/s10434-016-5146-y","volume":"23","author":"C Zinzindohoue","year":"2016","unstructured":"Zinzindohoue C, Bertrand P, Michel A, et al. A prospective study on skin-sparing mastectomy for immediate breast reconstruction with latissimus dorsi flap after neoadjuvant chemotherapy and radiotherapy in invasive breast carcinoma. Ann Surg Oncol. 2016;23(7):2350\u20136.","journal-title":"Ann Surg Oncol."},{"key":"5364_CR51","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1093\/annonc\/mdt129","volume":"24","author":"C Criscitiello","year":"2013","unstructured":"Criscitiello C, Azim HA Jr, Agbor-tarh D, et al. Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial. Ann Oncol. 2013;24:1980\u20135.","journal-title":"Ann Oncol."},{"key":"5364_CR52","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1002\/bjs.9545","volume":"101","author":"S Kummel","year":"2014","unstructured":"Kummel S, Holtschmidt J, Loibl S. Surgical treatment of primary breast cancer in the neoadjuvant setting. Br J Surg. 2014;101:912\u201324.","journal-title":"Br J Surg."},{"key":"5364_CR53","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.jamcollsurg.2015.02.011","volume":"220","author":"BK Killelea","year":"2015","unstructured":"Killelea BK, Yang VQ, Mougalian S, et al. Neoadjuvant chemotherapy for breast cancer increases the rate of breast conservation: results from the National Cancer Database. J Am Coll Surg. 2015;220:1063\u20139.","journal-title":"J Am Coll Surg."},{"key":"5364_CR54","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1245\/s10434-015-4714-x","volume":"22","author":"PJ Graham","year":"2015","unstructured":"Graham PJ, Brar MS, Foster T, et al. Neoadjuvant chemotherapy for breast cancer, is practice changing? A population-based review of current surgical trends. Ann Surg Oncol. 2015;22:3376\u201382.","journal-title":"Ann Surg Oncol."},{"key":"5364_CR55","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1245\/s10434-012-2525-x","volume":"19","author":"CS Fisher","year":"2012","unstructured":"Fisher CS, Martin-Dunlap T, Ruppel MB, Gao F, Atkins J, Margenthaler JA. Fear of recurrence and perceived survival benefit are primary motivators for choosing mastectomy over breast-conservation therapy regardless of age. Ann Surg Oncol. 2012;19:3246\u201350.","journal-title":"Ann Surg Oncol."},{"key":"5364_CR56","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0002-9610(00)00501-8","volume":"180","author":"RJ Nold","year":"2000","unstructured":"Nold RJ, Beamer RL, Helmer SD, McBoyle MF. Factors influencing a woman\u2019s choice to undergo breast-conserving surgery versus modified radical mastectomy. Am J Surg. 2000;180:413\u20138.","journal-title":"Am J Surg."},{"key":"5364_CR57","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1470-2045(13)70166-9","volume":"14","author":"T Kuehn","year":"2013","unstructured":"Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14:609\u201318.","journal-title":"Lancet Oncol."},{"key":"5364_CR58","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1093\/annonc\/mdv161","volume":"26","author":"V Bossuyt","year":"2015","unstructured":"Bossuyt V, Provenzano E, Symmans WF, et al. Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. Ann Oncol. 2015;26:1280\u201391.","journal-title":"Ann Oncol."},{"key":"5364_CR59","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/jso.21911","volume":"104","author":"VK Tan","year":"2011","unstructured":"Tan VK, Goh BK, Fook-Chong S, Khin LW, Wong WK, Yong WS. The feasibility and accuracy of sentinel lymph node biopsy in clinically node-negative patients after neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis. J Surg Oncol. 2011;104:97\u2013103.","journal-title":"J Surg Oncol."},{"key":"5364_CR60","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/bjs.5209","volume":"93","author":"Y Xing","year":"2006","unstructured":"Xing Y, Foy M, Cox DD, Kuerer HM, Hunt KK, Cormier JN. Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. Br J Surg. 2006;93:539\u201346.","journal-title":"Br J Surg."},{"key":"5364_CR61","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.acra.2009.01.026","volume":"16","author":"AM Kelly","year":"2009","unstructured":"Kelly AM, Dwamena B, Cronin P, Carlos RC. Breast cancer sentinel node identification and classification after neoadjuvant chemotherapy-systematic review and meta analysis. Acad Radiol. 2009;16:551\u201363.","journal-title":"Acad Radiol."},{"key":"5364_CR62","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.1016\/j.ejca.2009.08.001","volume":"45","author":"CH Deurzen van","year":"2009","unstructured":"van Deurzen CH, Vriens BE, Tjan-Heijnen VC, et al. Accuracy of sentinel node biopsy after neoadjuvant chemotherapy in breast cancer patients: a systematic review. Eur J Cancer. 2009;45:3124\u201330.","journal-title":"Eur J Cancer."},{"key":"5364_CR63","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1200\/JCO.2008.18.3228","volume":"27","author":"JM Classe","year":"2009","unstructured":"Classe JM, Bordes V, Campion L, et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study. J Clin Oncol. 2009;27:726\u201332.","journal-title":"J Clin Oncol."},{"key":"5364_CR64","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S1470-2045(13)70411-X","volume":"14","author":"A Robidoux","year":"2013","unstructured":"Robidoux A, Tang G, Rastogi P, et al. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. Lancet Oncol. 2013;14:1183\u201392.","journal-title":"Lancet Oncol."},{"key":"5364_CR65","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1002\/cncr.25152","volume":"116","author":"LS Dominici","year":"2010","unstructured":"Dominici LS, Negron Gonzalez VM, Buzdar AU, et al. Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer. Cancer. 2010;116:2884\u20139.","journal-title":"Cancer."},{"key":"5364_CR66","doi-asserted-by":"crossref","first-page":"9304","DOI":"10.1200\/JCO.2005.02.5023","volume":"23","author":"BT Hennessy","year":"2005","unstructured":"Hennessy BT, Hortobagyi GN, Rouzier R, et al. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol. 2005;23:9304\u201311.","journal-title":"J Clin Oncol."},{"key":"5364_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2016.02.009","author":"K Enokido","year":"2016","unstructured":"Enokido K, Watanabe C, Nakamura S, et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with an initial diagnosis of cytology-proven lymph node-positive breast cancer. Clin Breast Cancer. 2016. doi: 10.1016\/j.clbc.2016.02.009 .","journal-title":"Clin Breast Cancer."},{"key":"5364_CR68","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/SLA.0000000000000551","volume":"261","author":"JC Boughey","year":"2015","unstructured":"Boughey JC, Suman VJ, Mittendorf EA, et al. Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 (Alliance). Ann Surg. 2015;261:547\u201352.","journal-title":"Ann Surg."},{"key":"5364_CR69","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1001\/jama.2013.278932","volume":"310","author":"JC Boughey","year":"2013","unstructured":"Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310:1455\u201361.","journal-title":"JAMA."},{"key":"5364_CR70","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1200\/JCO.2014.57.8401","volume":"33","author":"JC Boughey","year":"2015","unstructured":"Boughey JC, Ballman KV, Hunt KK, et al. Axillary ultrasound after neoadjuvant chemotherapy and its impact on sentinel lymph node surgery: results from the American College of Surgeons Oncology Group Z1071 Trial (Alliance). J Clin Oncol. 2015;33:3386\u201393.","journal-title":"J Clin Oncol."},{"key":"5364_CR71","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1097\/SLA.0000000000001375","volume":"263","author":"JC Boughey","year":"2016","unstructured":"Boughey JC, Ballman KV, Le-Petross HT, et al. Identification and resection of clipped node decreases the false-negative rate of sentinel lymph node surgery in patients presenting with node-positive breast cancer (T0\u2013T4, N1\u2013N2) who receive neoadjuvant chemotherapy: results from ACOSOG Z1071 (Alliance). Ann Surg. 2016;263:802\u20137.","journal-title":"Ann Surg."},{"key":"5364_CR72","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1200\/JCO.2015.64.0094","volume":"34","author":"AS Caudle","year":"2016","unstructured":"Caudle AS, Yang WT, Krishnamurthy S, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol. 2016;34:1072\u20138.","journal-title":"J Clin Oncol."},{"key":"5364_CR73","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/00000658-199102000-00006","volume":"213","author":"JR Broadwater","year":"1991","unstructured":"Broadwater JR, Edwards MJ, Kuglen C, Hortobagyi GN, Ames FC, Balch CM. Mastectomy following preoperative chemotherapy: strict operative criteria control operative morbidity. Ann Surg. 1991;213:126\u20139.","journal-title":"Ann Surg."},{"key":"5364_CR74","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.surg.2012.05.001","volume":"152","author":"MR Decker","year":"2012","unstructured":"Decker MR, Greenblatt DY, Havlena J, Wilke LG, Greenberg CC, Neuman HB. Impact of neoadjuvant chemotherapy on wound complications after breast surgery. Surgery. 2012;152:382\u20138.","journal-title":"Surgery."},{"key":"5364_CR75","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa1111097","volume":"366","author":"HD Bear","year":"2012","unstructured":"Bear HD, Tang G, Rastogi P, et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med. 2012;366:310\u201320.","journal-title":"N Engl J Med."},{"key":"5364_CR76","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1200\/JCO.2014.57.0572","volume":"33","author":"WM Sikov","year":"2015","unstructured":"Sikov WM, Berry DA, Perou CM, et al. Impact of the addition of carboplatin and\/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015;33:13\u201321.","journal-title":"J Clin Oncol."},{"key":"5364_CR77","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/S1470-2045(15)70137-3","volume":"16","author":"HM Earl","year":"2015","unstructured":"Earl HM, Hiller L, Dunn JA, et al. Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial. Lancet Oncol. 2015;16:656\u201366.","journal-title":"Lancet Oncol."},{"key":"5364_CR78","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1245\/s10434-014-3606-9","volume":"21","author":"B Gerber","year":"2014","unstructured":"Gerber B, von Minckwitz G, Eidtmann H, et al. Surgical outcome after neoadjuvant chemotherapy and bevacizumab: results from the GeparQuinto study (GBG 44). Ann Surg Oncol. 2014;21:2517\u201324.","journal-title":"Ann Surg Oncol."},{"issue":"24 Suppl","key":"5364_CR79","doi-asserted-by":"crossref","first-page":"PD07-08","DOI":"10.1158\/0008-5472.SABCS11-PD07-08","volume":"71","author":"H Bear","year":"2011","unstructured":"Bear H, Tang G, Rastogi P, et al. PD07-08: the effect on surgical complications of bevacizumab added to neoadjuvant chemotherapy: NSABP Protocol B-40. Cancer Res. 2011;71(24 Suppl):PD07-08.","journal-title":"Cancer Res."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-016-5364-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-016-5364-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-016-5364-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T09:42:08Z","timestamp":1568108528000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-016-5364-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,30]]},"references-count":79,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["5364"],"URL":"https:\/\/doi.org\/10.1245\/s10434-016-5364-3","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,30]]}}}